Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia  by DeRubertis, Brian G. et al.
From the New England Society for Vascular Surgery
Reduced primary patency rate in diabetic patients
after percutaneous intervention results from more
frequent presentation with limb-threatening
ischemia
Brian G. DeRubertis, MD, Matthew Pierce, BS, Evan J. Ryer, MD, Susan Trocciola, MD,
K. Craig Kent, MD, and Peter L. Faries, MD, New York, NY
Objective: Although patients with diabetes are at increased risk of amputation from peripheral vascular disease, excellent
limb-salvage rates have been achieved with aggressive surgical revascularization. It is less clear whether patients with
diabetes will fare as well as nondiabetics after undergoing percutaneous lower extremity revascularization, a modality
which is becoming increasingly utilized for this disease process. This study aimed to assess differential outcomes in
between diabetics and nondiabetics in lower extremity percutaneous interventions.
Methods: We retrospectively studied 291 patients with respect to patient variables, complications, and outcomes for
percutaneous interventions performed for peripheral occlusive disease between 2002 and 2005. Tibial vessel run-off was
assessed by angiography. Patency (assessed arterial duplex) was expressed by Kaplan-Meier method and log-rank analysis.
Mean follow-up was 11.6 months (range 1 to 56 months).
Results:A total of 385 interventions for peripheral occlusive disease with claudication (52.2%), rest pain (16.4%), or tissue
loss (31.4%) were analyzed, including 336 primary interventions and 49 reinterventions (mean patient age 73.9 years,
50.8%male). Comorbidities included diabetes mellitus (57.2%), chronic renal insufficiency (18.4%), hemodialysis (3.8%),
hypertension (81.9%), hypercholesterolemia (57%), coronary artery disease (58%), tobacco use (63.2%). Diabetics were
significantly more likely to be female (55.3% vs 40.8%), and suffer from CRI (23.5% vs 12.0%), a history of myocardial
infarction (36.5% vs 18.0%), and <three-vessel tibial outflow (83.5% vs 71.8%), compared with nondiabetics, although
all other comorbidities and lesion characteristics were equivalent between these groups. Overall primary patency ( SE)
at 6, 12, and 18months was 85 2%, 63 3% and 56 4%, respectively. Patients with diabetes suffered reduced primary
patency at 1 year compared with nondiabetics. For nondiabetics, primary patency was 88  2%, 71  4%, and 58  4%
at 6, 12, and 18 months, while for diabetics it was 82  2%, 53  4%, and 49  4%, respectively (P  .05). Overall
secondary patency at 6, 12, and 18 months was 88  2%, 76  3%, and 69  3%, and did not vary by diabetes status.
One-year limb salvage rate was 88.3% for patients with limb-threatening ischemia, which was also similar between
diabetics and nondiabetics. While univariate analysis revealed that female gender, <three-vessel tibial outflow, and a
history of tobacco use were all predictive of reduced primary patency (P < .05), none of these factors significantly
impacted secondary patency or limb-salvage rate. Furthermore, only limb-threatening ischemia remained a significant
predictor of outcome on multivariate analysis, suggesting that the poorer primary patency in diabetics is related primarily
to their propensity to present with limb-threatening disease compared with nondiabetics.
Conclusion: Patients with diabetes demonstrate reduced primary patency rates after percutaneous treatment of lower
extremity occlusive disease, most likely due to their advanced stage of disease at presentation. However, despite a higher
reintervention rate, diabetics and others with risk factors predictive of reduced primary patency can attain equivalent
short-term secondary patency and limb-salvage rates. Therefore, these patient characteristics should not be considered
contraindications to endovascular therapy. (J Vasc Surg 2008;47:101-8.)Previously, percutaneous lower extremity revascular-
ization was offered only to patients who had contraindica-
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doi:10.1016/j.jvs.2007.09.018tions to open surgical bypass or had exhausted all surgical
options. In recent years, however, an increasing number of
patients have undergone percutaneous intervention as a
first-line therapy for occlusive disease of the lower extrem-
ity, and this includes both patients with claudication and
limb-threatening ischemia. Modalities available include not
only angioplasty and stenting of the target lesion, but also
excisional atherectomy, cryoplasty, and other adjuncts to
increase the technical success rate and perhaps the long-
term patency rates. In fact, as experience has grown and
results have become more clearly defined, these techniques
have become first-line therapy in many centers for patients
with this difficult disease.
Diabetes is a common comorbid condition in patients
with peripheral occlusive disease and is increasing in prev-
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January 2008102 DeRubertis et alalence.1,2 Diabetics with peripheral occlusive disease carry a
considerably worse prognosis than those without diabetes.3
These patients tend to have higher rates of significant
comorbidities, are more likely to suffer subsequent infec-
tious complications, and have a pattern of occlusive disease
which is more distal in nature and may pose increased
difficulty for endoluminal therapy.3,4 As a consequence,
diabetic patients are more likely to undergo amputation
than nondiabetics.3,4 However, through aggressive revas-
cularization efforts, including open distal bypass with au-
tologous conduit, many groups have been able to attain
limb-salvage rates in diabetics that are comparable with
nondiabetics.5-7
Despite good outcomes with open surgical bypass in
diabetics, it is less clear whether percutaneous interventions
for occlusive disease in these patients will be equally effec-
tive. Lessons learned from interventions in the coronary
circulation may suggest otherwise. Diabetes has been
shown to be a negative prognostic factor for all modalities
of coronary revascularization, and randomized trials of
coronary artery bypass grafting vs percutaneous interven-
tions have consistently demonstrated survival benefit and
increased freedom from coronary events with surgery rela-
tive to percutaneous procedures.8-10 High rates of occlu-
sive-type restenosis and smaller vessel caliber have been
cited as reasons for poorer results in these patients.11-13 It is
unclear whether such patterns noted in the coronary circu-
lation will hold true for percutaneous interventions per-
formed in the peripheral circulation in diabetics. The pur-
pose of this manuscript is to better understand the results of
infrainguinal angioplasty, stenting, and atherectomy in pa-
tients with diabetes and to analyze factors associated with
treatment failure in these patients.
METHODS
A retrospective search of the institutional database was
performed to identify all patients between 2001 and 2005
who underwent percutaneous infrainguinal lower extrem-
ity revascularization for primary arterial lesions (both ste-
noses and occlusions) performed by the Division of Vascu-
lar Surgery of the New York Presbyterian Hospital.
Procedures were limited to infrainguinal interventions
without concomitant iliac inflow procedures in patients
without prior open revascularizations. Indications for the
procedure included disabling claudication or limb-threat-
ening ischemia (defined as rest pain or tissue loss/ulcer-
ation). Patients, who had prior lower extremity bypass
surgery (15 patients) or a presentation of acute lower
extremity ischemia requiring emergent revascularization
(12 patients), were excluded from analysis. All patients
were entered into a database along with complete demo-
graphic information, comorbidities, and perioperative
events (death, major and minor complications, and return
to the operating room). Operative reports and procedural
logs were reviewed for all interventions to determine type
and location of treated lesions, as well as other procedural
characteristics. Angiograms were reviewed to stratify fem-
oropopliteal lesions by Transatlantic Inter-Society Consen-sus (TASC) classification, classify tibial lesions as stenoses
or occlusions, and evaluate number of pre- and postopera-
tive tibial runoff vessels.14 All patients were crossed-refer-
enced with the vascular lab database to identify pre- and
postoperative vascular lab data.
During this period, percutaneous revascularization be-
came the first-line modality for the division for patients
with chronic limb ischemia excluding those with isolated
common femoral artery disease. The range of interventions
included angioplasty with and without stent placement,
cryoplasty balloon angioplasty (generally for restenotic le-
sions), laser angioplasty, and excisional atherectomy. A
contralateral approach was used in the majority of interven-
tions while an ipsilateral antegrade approach was generally
employed when isolated tibial disease was anticipated from
preoperative studies. Procedures were performed either
with a portable imaging fluoroscopic C-arm (OEC 9800;
GE Medical Systems, Milwaukee, Wis) or in the angio-
equipped operating room using fixed fluoroscopic equip-
ment (Siemens, Munich, Germany). Iodinated contrast was
used in patients with normal creatinine, and gadolium
alone or combination gadolinium plus iodinated contrast
was used in patients with creatinine level greater that
1.3mg/dl. All patients were anticoagulated with intrave-
nous heparin (100 units/kg) before lesion crossing, and
activating clotting time was maintained above 250 seconds.
All procedures were performed under local anesthesia with
intravenous sedation. All patients not currently taking aspi-
rin were started on 325 mg per day at the preoperative
office visit and continued postoperatively unless contrain-
dicated. For patients undergoing stent placement or
atherectomy, a loading dose of Plavix 450 mg was admin-
istered in the post-anesthesia care unit, followed by 75mg/
day for 30 days.
Technique. Lesions were crossed with either luminal
or sub-intimal technique using hydrophilic guide wires
(0.035, 0.018, or 0.014 inch). Wires were supported using
4F and 5F angled glide catheters (Angiodynamics, Queens-
bury, NY) or Quick Cross catheters (Spectranetics, Colo-
rado Springs, Colo). Re-entry into the luminal space was
confirmed by angiography before further intervention. Bal-
loon angioplasty was performed with appropriately sized
noncompliant balloons for the treated vessel, with inflation
times ranging from 60 to 120 seconds at 6 to 15 ATM of
pressure. Stenting was performed selectively for 30% re-
sidual stenosis or flow limiting dissections. Excisional
atherectomy was used as an alternative to balloon angio-
plasty in 57 (14.8%) cases, most commonly in the popliteal
and tibial circulation. The Silverhawk atherectomy device
(Fox Hollow Industries, Redwood City, Calif) was used for
all atherectomies and performed over a 0.014 system. Pre-
or postatherectomy adjunctive procedures including angio-
plasty or angioplasty/stenting were required in 21.8% of
cases either to allow passage of the atherectomy device or to
treat residual disease following atherectomy. Completion
angiography with distal runoff was performed following
intervention.
arter
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analysis was determined primarily by arterial duplex or
angiography, and loss of patency was defined as occlusion,
50% stenosis, or an elevated ratio of greater than four
times the velocity of the more proximal segment. In the
absence of angiography or arterial duplex exam results,
hemodynamic parameters (decrease in ankle-brachial index
of 0.2 during follow-up or loss of a previously palpable
pulse) or clinical parameters (recurrence of symptoms in
patients with claudication and failure of wound healing or
need for major amputation in those with critical limb
ischemia) were used as surrogates for patency assessment
(less than 15% of patients).Percutaneous treatment failure
was defined as loss of patency by anatomic, hemodynamic,
or clinical measures without effective revascularization by
the conclusion of the study period. Patients were evaluated
1 month postoperatively, then every 3 months thereafter.
Statistical analysis. Demographic information was
tabulated for all patients and expressed as percentage 
standard deviation. Univariate analysis of dichotomous
variables between subgroups was performed by Fisher exact
t-test. Multivariate logistic regression analysis was per-
formed to assess factors that were significant on univariate
analysis. Kaplan-Meier survival curves for primary and sec-
ondary patency and limb salvage rates were computed and
subgroups were compared by log-rank analysis to deter-
mine factors predictive of treatment failure.
RESULTS
Demographics and disease patterns. A total of 385
percutaneous interventions were performed on 291 pa-
tients. This included 336 primary interventions (limbs) and
49 reinterventions. Indications included claudication in
201 interventions (52.2%), rest pain in 63 interventions
(16.4%), and gangrene or tissue loss in 121 interventions
(31.4%). Patients presenting with acute ischemia were ex-
cluded from analysis. Demographic information and pa-
tient comorbidities are listed in Table I. The mean age
overall was 73.9 years (range 38 to 95 years) and was
Table I. Demographics and comorbidities in patients und
Diabetics N (%)
Total 166
Age (y) 73.0
Male 74 (44.7%)
Diabetes —
Tobacco use (any) 106 (63.9%)
Current tobacco use 23 (13.9%)
Hypertension 142 (85.6%)
Hypercholesterolemia 94 (56.9%)
Chronic renal insufficiency 39 (23.5%)
ESRD 9 (5.4%)
Prior MI 61 (36.5%)
Coronary artery disease 103 (62.1%)
Prior CABG 32 (19.2%)
ESRD, End stage renal disease; MI, myocardial infarction; CABG, coronarystatistically equivalent between diabetics and nondiabetics.Diabetes (either type I or II) was present in 57.2% of
patients, and other common comorbidities included his-
tory of tobacco use in 63.2%, hypertension in 81.9%, hy-
percholesterolemia in 57.0%, and coronary artery disease in
58.1%. Diabetics and nondiabetics were similar in clinical
characteristics except for the proportion with chronic renal
insufficiency (23.5% vs 12.0%, respectively, P  .025),
history of myocardial infarction (36.5% vs 18.0%, respec-
tively, P  .001), female gender (55.3% vs 40.8%, respec-
tively, P  .025), and limb-threat as the procedural indica-
tion, which were all statistically more prevalent in the
diabetic patients than nondiabetics. Limb-threat was the
indication for intervention in 52.5% of diabetic patients and
only 36.2% of nondiabetics (P  .004). Diabetic patients
had a lower likelihood of three-vessel runoff in the lower leg
(16.5% vs 28.2%, P  0.05) but this trend was not statisti-
cally significant (see Table II). There were also no differ-
ences between TASC stratification of femoropopliteal le-
sions in these patients (P  .10).
Outcomes. Primary and secondary patency rates for all
interventions and limb-salvage rate for patients with critical
limb ischemia (rest pain or tissue loss) are demonstrated in
Kaplan-Meier curves in Fig 1. Mean follow-up time was
11.6 months. Overall 6-, 12-, and 18-month primary pa-
tency rates were 85  2%, 63  3%, and 56  4%, while
secondary patency rates were significantly higher at 88 
2%, 76  3%, and 69  3% (P  .001). Limb-salvage rates
over the same intervals were 94  2%, 88  3%, and 88 
3%. The strongest predictor of primary patency was indica-
tion for intervention, with claudicants having significantly
higher rates at 12- and 24-months (68 4% and 60 5%,
respectively) than those with limb-threat (54  5% and 43
 7%, respectively, P  .03). When patency rates were
stratified by presence or absence of diabetes and compared
by log-rank analysis, patients with diabetes were noted to
have a reduced primary patency rate compared with non-
diabetics (see Fig 2). The 6-, 12-, and 18-month primary
patency rates were 82  2%, 53  4%, and 49  4% with a
mean patency of 24.1 months for diabetics compared with
ing percutaneous lower extremity revascularization
ndiabetics N (%) All N (%) P value
125 291
75.7 73.9 ns
74 (59.2%) 148 (50.8%) P  .025
— 166 (57.2%) —
78 (62.4%) 184 (63.2%) ns
21 (16.8%) 44 (15.0%) ns
96 (76.8%) 238 (81.9%) ns
72 (57.6%) 166 (57%) ns
15 (12.0%) 54 (18.4%) P  .025
2 (1.6%) 11 (3.8%) ns
23 (18.4%) 84 (28.9%) P  .001
66 (52.8%) 169 (58.1%) ns
29 (23.2%) 61 (20.8%) ns
y bypass grafting.ergo
No88  1%, 71  4%, and 58  4% with a mean patency of
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difference did not persist in these patients when examining
secondary patency rates, as 6-, 12-, and 18-month patency
for diabetics and nondiabetics was 88  3%, 72  4%, and
67  5%, and 89  3%, 75 5%, and 67  6%, respectively
(Fig 3, P  .66). Limb-salvage rates for diabetics and
nondiabetics were also equivalent by log-rank analysis (Fig
4, P  .77). While univariate analysis also revealed that
female gender (P  .03),  three-vessel tibial outflow (P 
.04), and a history of tobacco use (P  .05) were all
predictive of reduced primary patency (Table III), none of
these factors significantly impacted secondary patency or
limb-salvage rate. Furthermore, only limb-threatening
ischemia remained a significant predictor of outcome on
multivariate analysis (odds ratio 1.68, 95% confidence in-
terval 1.18 to 2.61, P  .021, see Table IV), suggesting
that the poorer primary patency in diabetics is related
Table II. Characteristics of treated lesions in diabetic and
Diabetics
Number of runoff vessels (n  184†)
Three-vessel 16 (16.5%)
Two-vessel 38 (39.2%)
Single-vessel 43 (44.3%)
TASC classification* (n  385)
TASC A 9 (4.1%)
TASC B 59 (26.8%)
TASC C 85 (38.6%)
TASC D 67 (30.5%)
*For femoropopliteal lesions.
†Full completion angiograms of lower leg available for review.
Fig 1. Primary and secondary patency rates for all interventions
and limb-salvage rates for patients with limb-threatening ischemia
expressed by Kaplan-Meier curves. The differences between each
curve were highly significant on log-rank analysis.primarily to their advanced disease stage and propensity topresent with limb-threatening ischemia relative to nondia-
betics.
The correlation between number of runoff vessels and
primary patency rates is demonstrated in Fig 5.Patients
with three-vessel runoff had the most favorable outcomes
with 90  5%, 79  9%, and 79  9% patency at 6-, 12-,
and 18-months. This was significantly higher than patients
with one- or two-vessel runoff who attained patency rates
of 85  3%, 52  6%, and 39  7% over the same interval
(P  .04). Patency rates between subgroups with one- or
two-vessel runoff did not vary significantly. Finally, the
1-year primary patency varied by level of intervention.
Tibial interventions were associated with a primary patency
rate of 57  7%, compared with 74  5% for femoral
intervention.
Diabetic patients were more likely to suffer an initial
diabetic patients
Nondiabetics All P value
25 (28.7%) 40 (22.0%) P  .05, ns
29 (33.3%) 67 (36.4%)
33 (37.9%) 77 (41.6%)
10 (6.1%) 20 (5.2%) P  .10, ns
46 (27.8%) 111 (28.8%)
53 (32.2%) 135 (35.1%)
56 (33.9%) 119 (30.9%)
Fig 2. Primary patency rates for all treated limbs in diabetic and
nondiabetic patients. Diabetic patients showed significantly re-
duced primary patency on log-rank analysis (P  .05).nonfailure, thus resulting in a trend toward a higher reinterven-
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cance). Diabetics underwent reintervention in 20.7% com-
pared with 12.7% in nondiabetics (P  .10, ns, Table V). Of
the patients who suffered percutaneous treatment failures,
Fig 3. Secondary patency rate for all treated limbs in diabetic and
nondiabetic patients by Kaplan-Meier log-rank analysis. Unlike
primary patency, no difference in secondary patency rate was
observed when stratified by the presence of diabetes.
Fig 4. Limb-salvage rate for treated limbs in patients with critical
limb ischemia by Kaplan-Meier method. When compared by log-
rank analysis, no difference was observed in limb-salvage between
diabetics and nondiabetics.10 successfully underwent surgical bypass for limb-salvage,and 13 patients underwent major amputation. The percent
of patients undergoing surgical bypass, amputation, and
other failures of percutaneous therapy was identical be-
tween diabetics and nondiabetics. The 13 patients who
underwent amputation had no available options for surgical
reconstruction prior to percutaneous therapy. Review of
pre- and postintervention angiograms were performed in all
patients who underwent bypass or amputation specifically
to address the effect of percutaneous treatment failure on
location of bypass target site. No patients were identified
who required a more distal bypass or higher amputation
because of failed percutaneous treatment. Most complica-
tions were access-related and included groin hematoma in
9.3%, pseudoaneurysm in 3.9%, renal dysfunction (eleva-
tion in serum creatinine  0.5 mg/dl) in 6.0%, wound
infection in 1.9%, and 1.0% mortality rate.
DISCUSSION
Chronic limb ischemia continues to be a debilitating
condition, which requires a carefully planned treatment
strategy and a multidisciplinary approach, in order to attain
optimal results. The gold standard and mainstay of therapy
and has long been considered open surgical bypass for
restoration of pulsatile flow to the distal lower extremity.
Lower extremity bypass has been applied very successfully
even in difficult clinical scenarios, including the treatment
of patients with diabetic foot gangrene and other condi-
tions which carry a high risk of amputation.15-16 Multiple
Table III. Univariate analysis of risk factors for reduced
primary patency following percutaneous revascularization
P value
Critical limb ischemia .01
Female gender .03
Diabetes .05
Tobacco use .05
 Three-vessel runoff .04
Hypertension .80
Hypercholesterolemia .79
Chronic renal insufficiency (Cr  1.2) .31
ESRD .21
Coronary artery disease .80
*ESRD, End stage renal disease.
Table IV. Multivariate analysis of risk factors for reduced
primary patency following percutaneous revascularization
Odds ratio
95% confidence
interval P value
Limb-threatening
ischemia
1.680 1.180 2.612 .021
Diabetes 1.341 0.852 2.109 .205, ns
Male gender 0.761 0.487 1.189 .230, ns
Three-vessel runoff 0.705 0.459 1.083 .110, ns
Tobacco use (any) 1.158 0.750 1.787 .508, ns
Inclusion of risk factors with P  .10 on univariate analysis.authors have demonstrated comparable limb salvage rates
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bidities and the challenging pattern of arterial disease in
these patients.5-7
Recently, the treatment of chronic lower extremity
ischemia has undergone a paradigm shift at many centers
toward an endovascular approach.17-19 Developments in
endovascular technology as well as the rapid and successful
dissemination of endovascular skills to vascular surgeons
has allowed for the application of these techniques as the
initial diagnostic and therapeutic intervention in the con-
tinuum of care that a surgeon provides for these pa-
tients.20-22 At our institution, like many major centers,
percutaneous revascularization has evolved over the last 5
years into the primary modality for treating lower extremity
occlusive disease, with open surgical bypass reserved for
those patients who fail percutaneous intervention.
One of the unresolved issues in percutaneous treatment
of lower extremity occlusive disease centers on the role of
endovascular therapy in diabetics, as these patients have
been shown to be at risk for poorer outcomes after percu-
taneous revascularization of the coronary circulation com-
pared with coronary bypass. To investigate the relationship
between diabetics and outcomes following percutaneous
intervention in the peripheral circulation, we reviewed our
experience with all lower extremity percutaneous interven-
tions including balloon and laser angioplasty, angioplasty
and stent placement, and excision atherectomy in diabetic
and nondiabetic patients. Although outcomes were not
widely disparate between these groups, diabetics did show a
Fig 5. Primary patency rates for all treated limbs stratified by
number of tibial outflow vessels and expressed by Kaplan-Meier
method. Patients with reduced tibial outflow (three-vessel run-
off) showed significantly reduced patency relative to patients with
three-vessel runoff (P  .04).reduced primary patency rate relative to nondiabetics. Thisis congruent with other reports in which diabetes has been
found to be an independent predictor of failure in percuta-
neous lower extremity interventions.19,23-25 Interestingly,
however, this reduced patency did not translate to reduced
secondary patency or limb-salvage rates. While it is possible
that these curves will further diverge to statistical signifi-
cance with longer follow-up or increased number of pa-
tients, it appears that in the short term, the poorer results in
diabetics can be overcome by aggressive follow-up, surveil-
lance, and reintervention. As shown in Table V, diabetics
showed a trend toward higher reintervention rates, and the
successful revascularization attained by these procedures is
likely the reason diabetics showed no difference in ampu-
tation, bypass, or failed endovascular treatment rates com-
pared with nondiabetics. Indeed, a prior analysis of out-
comes following failure of percutaneous intervention
demonstrated that failures could be salvaged by a repeat
endovascular procedure in 82% of cases and could do so
with little morbidity.24 Alternatively, it is possible that the
limited mean follow-up time of 11.6 months has not yet
allowed an eventual separation in the secondary patency or
limb-salvage curves for diabetics and nondiabetics to be
realized, and this may become evident with increased
follow-up.
Others have shown that patency rates can be correlated
to infrageniculate runoff, a finding which is demonstrated
in our results as well.19,23,26,27 Decreased primary patency
was evident in patients with one to two runoff vessels
compared with three-vessel runoff. While we believe that
reduced tibial outflow may be a causative factor in the
reduced primary patency of percutaneous interventions, it
is also possible that it is simply amarker for increased disease
severity. Those with more severe or extensive disease may
be more likely to re-present with recurrent symptoms,
therefore leading to more frequent documentation of fail-
ure in this group relative to those with three-vessel runoff.
Although diabetics often have distal tibial disease and this
can be a confounding factor in regards to primary patency
in diabetics, these patients did not have a significantly lower
number of runoff vessels than nondiabetic counterparts in
this series, and, thus, the decreased primary patency of
diabetic patients is likely independent of runoff vessel.
Women were demonstrated to have reduced primary pa-
tency in this series as well. This is a finding which was
unanticipated and not well detailed in the literature, but is
likely explained at least in part by the preponderance of
females in the subgroup of diabetics.
Another factor which correlated with reduced primary
patency in our study includes critical limb ischemia com-
pared with claudication as an indication for intervention.
While this finding is not universally true in prior studies, it
is a well-documented phenomenon.24,28 Importantly, this
was the single risk factor which remained predictive of
reduced primary patency on multivariate analysis. This ar-
gues that the reduced patency in diabetic patients is largely
a result of their propensity to present with limb-threatening
ischemia, as this was the indication for intervention in
52.5% of diabetics and only 36.2% of nondiabetics. It is
eters
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those of all patients with limb-threatening ischemia and
include a composite of such factors as TASC classification,
tibial runoff, level of most distal intervention, multilevel
intervention, and other similar factors.
We did not find chronic renal insufficiency or hyperten-
sion to be a risk factor for failure as several other studies
have demonstrated.23,29 The results demonstrate a nonsig-
nificant trend toward reduced patency in patients on hemo-
dialysis for end-stage renal disease, but the small sample size
(n  11) of patients with this condition prevents definitive
conclusions to be drawn in this series.
The nonrandomized nature of this study is one of its
significant limitations and has likely introduced a significant
degree of treatment bias. Furthermore, when divided into
different groups by treatment modality, the numbers of
patients in each group become too small to make definitive
conclusions regarding efficacy of one modality compared
with another. Further study and larger sample sizes will be
necessary to more accurately compare different modalities.
In conclusion, diabetic patients are more likely to suffer
reduced primary patency rates compared with nondiabetics
following lower extremity percutaneous revascularization,
likely as a result of their tendency to present with limb-
threatening ischemia. While this fact should be considered
when planning surgical intervention in these patients, it is
also true that secondary patency rates and limb-salvage
rates, at least in the intermediate term, appear equivalent to
nondiabetics. While it is possible that further follow-up will
divulge a separation in the secondary patency and limb-
salvage curves in these subgroups, it also may be the case
that reintervention in those that fail can provide compara-
ble outcomes with those in lower risk subgroups.
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